Klotho Neurosciences Abandons Turn Biotechnologies Deal, Focusing on Longevity Medicine Pipeline

Klotho Neurosciences has allowed its Letter of Intent with Turn Biotechnologies to expire, citing that the proposed transaction did not fit its long-term strategic plan. The company will focus on advancing its Klotho anti-aging protein research pipeline and development of treatments. The longevity medicine market is expected to grow rapidly, with the world's aging population projected to hit 2.1 billion by 2050 and drive healthcare costs to exceed $47 trillion by 2030.

Klotho Neurosciences (Nasdaq: KLTO) announced on October 7, 2025, that its Letter of Intent with Turn Biotechnologies has expired. The company's board of directors concluded that the proposed transaction did not align with Klotho's long-term strategic plan. Instead, Klotho will concentrate its resources on advancing its Klotho anti-aging protein research pipeline and developing treatments targeting longevity Klotho Neurosciences Announces Expiration of Letter of Intent^[1].

The decision to prioritize human Klotho protein programs is driven by the growing longevity medicine market and the increasing aging demographics. According to the World Health Organization, the global population aged 60 and above is projected to reach 2.1 billion by 2050, with healthcare costs expected to exceed $47 trillion by 2030 .

Klotho Neurosciences aims to capitalize on the expanding longevity market by focusing on its innovative Klotho anti-aging protein research. The company's strategic shift underscores the increasing importance of longevity medicine, which is expected to grow rapidly due to the aging population and rising healthcare costs.